Vivos Therapeutics (NASDAQ:VVOS) Stock Price Down 2.9% – Here’s What Happened

Shares of Vivos Therapeutics, Inc. (NASDAQ:VVOS) traded down 2.9% during mid-day trading on Monday . The company traded as low as $0.4125 and last traded at $0.4196. 171,717 shares were traded during trading, a decline of 82% from the average daily volume of 958,266 shares. The stock had previously closed at $0.4320.

Analyst Ratings Changes

VVOS has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Vivos Therapeutics in a research note on Monday, April 20th. HC Wainwright dropped their price objective on shares of Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating for the company in a research report on Friday, April 17th. Finally, Ascendiant Capital Markets upped their price objective on Vivos Therapeutics from $3.00 to $3.10 and gave the stock a “buy” rating in a report on Thursday, June 4th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $2.80.

Vivos Therapeutics Price Performance

The stock has a market cap of $5.83 million, a price-to-earnings ratio of -0.20 and a beta of 6.16. The firm has a 50 day simple moving average of $0.59 and a two-hundred day simple moving average of $1.19.

Vivos Therapeutics (NASDAQ:VVOS) last posted its earnings results on Wednesday, May 20th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.07). The company had revenue of $5.14 million for the quarter, compared to analyst estimates of $4.35 million. Vivos Therapeutics had a negative return on equity of 2,325.64% and a negative net margin of 127.70%. On average, sell-side analysts expect that Vivos Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vivos Therapeutics

Several large investors have recently bought and sold shares of VVOS. Connective Capital Management LLC bought a new stake in shares of Vivos Therapeutics in the 3rd quarter valued at $620,000. DRW Securities LLC boosted its stake in Vivos Therapeutics by 179.5% in the 4th quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock worth $235,000 after purchasing an additional 74,441 shares during the period. B. Riley Wealth Advisors Inc. acquired a new position in Vivos Therapeutics in the 2nd quarter worth $220,000. Sequoia Financial Advisors LLC bought a new position in Vivos Therapeutics during the 1st quarter worth about $28,000. Finally, XTX Topco Ltd bought a new position in Vivos Therapeutics during the 2nd quarter worth about $65,000. Institutional investors own 26.35% of the company’s stock.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.